276 related articles for article (PubMed ID: 19278957)
1. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor.
Su TP; Hayashi T; Vaupel DB
Sci Signal; 2009 Mar; 2(61):pe12. PubMed ID: 19278957
[TBL] [Abstract][Full Text] [Related]
2. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.
Fontanilla D; Johannessen M; Hajipour AR; Cozzi NV; Jackson MB; Ruoho AE
Science; 2009 Feb; 323(5916):934-7. PubMed ID: 19213917
[TBL] [Abstract][Full Text] [Related]
3. N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer's disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk.
Cheng D; Lei ZG; Chu K; Lam OJH; Chiang CY; Zhang ZJ
Alzheimers Res Ther; 2024 May; 16(1):95. PubMed ID: 38693554
[TBL] [Abstract][Full Text] [Related]
4. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Frecska E; Szabo A; Winkelman MJ; Luna LE; McKenna DJ
J Neural Transm (Vienna); 2013 Sep; 120(9):1295-303. PubMed ID: 23619992
[TBL] [Abstract][Full Text] [Related]
5. Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate.
Jiménez JH; Bouso JC
J Psychopharmacol; 2022 Aug; 36(8):905-919. PubMed ID: 35695604
[TBL] [Abstract][Full Text] [Related]
6. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
7. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.
Szabo A; Kovacs A; Frecska E; Rajnavolgyi E
PLoS One; 2014; 9(8):e106533. PubMed ID: 25171370
[TBL] [Abstract][Full Text] [Related]
8. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
Jacob MS; Presti DE
Med Hypotheses; 2005; 64(5):930-7. PubMed ID: 15780487
[TBL] [Abstract][Full Text] [Related]
9. N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain.
Szabó Í; Varga VÉ; Dvorácskó S; Farkas AE; Körmöczi T; Berkecz R; Kecskés S; Menyhárt Á; Frank R; Hantosi D; Cozzi NV; Frecska E; Tömböly C; Krizbai IA; Bari F; Farkas E
Neuropharmacology; 2021 Jul; 192():108612. PubMed ID: 34023338
[TBL] [Abstract][Full Text] [Related]
10. Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels.
Johannessen M; Fontanilla D; Mavlyutov T; Ruoho AE; Jackson MB
Am J Physiol Cell Physiol; 2011 Feb; 300(2):C328-37. PubMed ID: 21084640
[TBL] [Abstract][Full Text] [Related]
11. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
12. On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis.
Grammenos D; Barker SA
J Neural Transm (Vienna); 2015 Jun; 122(6):733-9. PubMed ID: 25362533
[TBL] [Abstract][Full Text] [Related]
13. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA
Psychopharmacology (Berl); 2022 Jun; 239(6):1749-1763. PubMed ID: 35064294
[TBL] [Abstract][Full Text] [Related]
14. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.
Wallach JV
Med Hypotheses; 2009 Jan; 72(1):91-4. PubMed ID: 18805646
[TBL] [Abstract][Full Text] [Related]
15. In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.
Vitale AA; Pomilio AB; Cañellas CO; Vitale MG; Putz EM; Ciprian-Ollivier J
J Nucl Med; 2011 Jun; 52(6):970-7. PubMed ID: 21622895
[TBL] [Abstract][Full Text] [Related]
16. Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT).
Witowski CG; Hess MR; Jones NT; Pellitteri Hahn MC; Razidlo J; Bhavsar R; Beer C; Gonzalez-Velazquez N; Scarlett CO; Wenthur CJ; von Salm JL
Eur J Pharm Sci; 2024 Aug; 199():106803. PubMed ID: 38788435
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
[TBL] [Abstract][Full Text] [Related]
18. Human psychopharmacology of N,N-dimethyltryptamine.
Strassman RJ
Behav Brain Res; 1996; 73(1-2):121-4. PubMed ID: 8788488
[TBL] [Abstract][Full Text] [Related]
19. The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells.
Szabo A; Kovacs A; Riba J; Djurovic S; Rajnavolgyi E; Frecska E
Front Neurosci; 2016; 10():423. PubMed ID: 27683542
[TBL] [Abstract][Full Text] [Related]
20. Neuropharmacology of N,N-dimethyltryptamine.
Carbonaro TM; Gatch MB
Brain Res Bull; 2016 Sep; 126(Pt 1):74-88. PubMed ID: 27126737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
